Product image of Lantus Solostar (Insulin Glargine) supplied by GNH India

Lantus Solostar

Active Ingredient:
Insulin Glargine
Origin:
EU

Lantus Solostar (Insulin Glargine)

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a 100 U/mL injectable solution (pre‑filled pen) for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients, providing basal insulin coverage to help maintain stable blood glucose levels.

GNH India supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insulin glargine is a long‑acting basal insulin used to manage blood glucose in diabetes mellitus.

  • Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels.
  • Type 2 diabetes mellitus: complements other antidiabetic agents to achieve basal insulin needs.
  • Diabetes requiring basal insulin support: offers once‑daily dosing to simplify insulin regimens.

How It Works

  • Insulin glargine binds to insulin receptors on peripheral tissues, mimicking endogenous insulin. Its altered amino‑acid sequence reduces self‑association, creating a steady, peak‑free insulin level that enhances glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production. This basal activity provides continuous glycaemic control over 24 hours after a single subcutaneous injection.

Side Effects

The most frequently reported adverse reactions with insulin glargine are related to its pharmacologic action and injection site.

Common Side Effects

  • Hypoglycemia: low blood glucose levels, especially if dosing is excessive.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: increase in body weight associated with improved glycaemic control.
  • Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects

  • Severe hypoglycemia: potentially life‑threatening low blood glucose requiring assistance.
  • Allergic reactions: rash, urticaria, or angioedema indicating hypersensitivity.
  • Anaphylaxis: rare systemic allergic response that can be fatal.
  • Edema: fluid accumulation leading to swelling, particularly in lower extremities.

Precautions & Warnings

When using insulin glargine, several precautions should be observed to ensure safe and effective therapy.

  • Dose adjustment: titrate dose based on frequent blood glucose monitoring.
  • Hypoglycemia risk: avoid administration if patient is already hypoglycaemic.
  • Renal or hepatic impairment: monitor closely as insulin clearance may be reduced.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Concomitant medications: be aware of drugs that may mask hypoglycemia symptoms.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insulin glargine may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid)

  • Sulfonylureas or meglitinides: combined use can cause severe hypoglycemia.
  • Beta‑blockers: may mask signs of hypoglycemia, complicating detection.
  • Alcohol: excessive intake can potentiate hypoglycemia.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: may enhance insulin’s glucose‑lowering effect.
  • Thiazide diuretics: can increase blood glucose, requiring dose adjustment.
  • Corticosteroids: may raise glucose levels, necessitating higher insulin doses.
  • Oral contraceptives: may affect insulin requirements during hormonal changes.

Frequently Asked Questions

Lantus Solostar is a pre‑filled pen containing insulin glargine, a long‑acting basal insulin indicated for the management of blood glucose in adults and children with type 1 or type 2 diabetes mellitus. It provides once‑daily insulin coverage to help maintain fasting and between‑meal glucose levels.

Insulin glargine mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. Its altered structure creates a slow, steady release after subcutaneous injection, producing a peak‑free, 24‑hour insulin level that promotes peripheral glucose uptake and suppresses hepatic glucose production, thereby stabilising blood sugar.

The dose of Lantus Solostar is individualized and determined by the prescribing healthcare professional based on the patient’s current glycaemic control, body weight, diet, and concurrent therapies. Patients should follow the prescriber’s instructions and adjust the dose only under medical supervision.

Safety of insulin glargine in pregnancy and lactation has not been fully established. It may be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lantus Solostar. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Compared with other basal insulins such as insulin detemir or NPH, insulin glargine offers a longer, peak‑free duration of action, allowing once‑daily dosing in most patients. Its predictable pharmacokinetic profile reduces variability, though individual response and cost considerations may influence the choice of therapy.

Unopened pens should be stored at 2‑8 °C, protected from light and not frozen. Once in use, the pen may be kept at room temperature (up to 30 °C) for up to 28 days, but should still be protected from extreme heat and direct sunlight. Do not shake the pen before use.

Lantus Solostar is injected subcutaneously into the abdomen, thigh or upper arm using the pre‑filled pen. The injection site should be rotated with each dose to reduce lipodystrophy. The pen delivers a fixed 100 U/mL concentration; the prescribed dose is selected by turning the dose selector to the required units.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical help if a severe reaction occurs.

Lantus Solostar should not be used by individuals with a known hypersensitivity to insulin glargine or any of the pen’s excipients. It is also contraindicated in patients experiencing hypoglycemia at the time of dosing. Clinical judgment is required for patients with unstable cardiovascular disease or severe renal/hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Glargine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT